PROCEPT BioRobotics Corporation announced on March 24, 2025, the results of the independent, investigator-initiated WATER III trial, which compared Aquablation therapy to laser enucleation for treating large prostates (80-180mL). The study, which treated 186 men, reported three-month primary safety and efficacy endpoints.
The trial demonstrated that Aquablation therapy delivered substantially similar symptom relief compared to laser enucleation. Crucially, Aquablation therapy showed significantly lower rates of ejaculatory dysfunction (14.8% vs. 77.1%) and stress incontinence (0% vs. 9.1%) at three months.
Additionally, the procedural transfusion rate in the Aquablation therapy arm was 0%, highlighting the safety and reproducibility of modern Aquablation techniques in managing bleeding risk. These findings reinforce Aquablation therapy's robust clinical foundation and its potential to become the BPH standard of care for all prostate sizes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.